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Acute- and late-phase matrix
metalloproteinase (MMP)-9 activity is
comparable in female and male rats after
peripheral nerve injury
Albert G. Remacle1, Swathi K. Hullugundi2,3, Jennifer Dolkas2,3, Mila Angert2,3, Andrei V. Chernov1,
Alex Y. Strongin1* and Veronica I. Shubayev2,3*
Abstract
Background: In the peripheral nerve, pro-inflammatory matrix metalloproteinase (MMP)-9 performs essential
functions in the acute response to injury. Whether MMP-9 activity contributes to late-phase injury or whether
MMP-9 expression or activity after nerve injury is sexually dimorphic remains unknown.
Methods: Patterns of MMP-9 expression, activity and excretion were assessed in a model of painful peripheral
neuropathy, sciatic nerve chronic constriction injury (CCI), in female and male rats. Real-time Taqman RT-PCR for
MMP-9 and its endogenous inhibitor, tissue inhibitor of metalloproteinase-1 (TIMP-1) of nerve samples over a 2-
month time course of CCI was followed by gelatin zymography of crude nerve extracts and purified MMP-9 from
the extracts using gelatin Sepharose-beads. MMP excretion was determined using protease activity assay of urine in
female and male rats with CCI.
Results: The initial upsurge in nerve MMP-9 expression at day 1 post-CCI was superseded more than 100-fold at
day 28 post-CCI. The high level of MMP-9 expression in late-phase nerve injury was accompanied by the reduction
in TIMP-1 level. The absence of MMP-9 in the normal nerve and the presence of multiple MMP-9 species (the
proenzyme, mature enzyme, homodimers, and heterodimers) was observed at day 1 and day 28 post-CCI. The
MMP-9 proenzyme and mature enzyme species dominated in the early- and late-phase nerve injury, consistent with
the high and low level of TIMP-1 expression, respectively. The elevated nerve MMP-9 levels corresponded to the
elevated urinary MMP excretion post-CCI. All of these findings were comparable in female and male rodents.
Conclusion: The present study offers the first evidence for the excessive, uninhibited proteolytic MMP-9 activity
during late-phase painful peripheral neuropathy and suggests that the pattern of MMP-9 expression, activity, and
excretion after peripheral nerve injury is universal in both sexes.
Background
Peripheral neuropathy arises from lesion and disease
affecting the peripheral nervous system. There are over
100 peripheral neuropathy types associated with metabolic
disease, nutritional deficiencies, trauma and exposure to
drugs, toxins, alcohol, and viral pathogens, with neuro-
logical symptoms including muscle weakness, numbness,
loss of autonomic functions, and debilitating neuropathic
pain [1]. The mechanisms underlying pathological changes
in peripheral neuropathy depend on the triggers and may
be influenced by biological variables, including sex and
gender. Recent experimental evidence highlighted distinct
immune response mechanisms to peripheral nerve injury
in the development of mechanical hypersensitivity in
female and male rodents [2]. These recent data added to
the body of evidence of sexual dimorphism in the
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formation of collateral axonal sprouting, cortical connect-
ivity, and the activities of brain-derived neurotrophic factor,
N-methyl-D-aspartate, and opioid receptors in the dam-
aged nervous system (reviewed in [3]).
The matrix metalloproteinase (MMP) family of calcium-
dependent zinc endopeptidases includes soluble (colla-
genases, gelatinases, matrilysins, and stromelysins) and
membrane-type MMPs [4]. The structure of soluble
MMP comprises an N-terminal inhibitory prodomain
followed by an active site catalytic domain, a flexible
linker region, and a C-terminal hemopexin domain.
MMPs are synthesized as latent inactive proenzymes
that require the proteolytic removal of their inhibitory
prodomain to expose the active site and generate the
catalytically active mature proteases. MMP proteolysis
regulates the levels and the functionality of extracellular
matrix components and cell surface signaling receptors [5].
In the damaged adult peripheral nerve, pro-inflammatory
MMP-9 (gelatinase B) is produced uniquely and immedi-
ately after injury by Schwann, endothelial, and immune
cells to regulate the blood-nerve barrier breakdown, im-
mune cell recruitment, glial activation, demyelination,
remyelination, and pain [6–16].
MMP activity is regulated by four tissue inhibitors of
MMPs (TIMPs), each comprised of the N-terminal inhibi-
tory and the C-terminal non-inhibitory domains. Among
TIMPs, TIMP-1 is the most efficient inhibitor of the pro-
inflammatory MMP-9 gelatinase [4]. In addition, TIMP-1
via its C-terminal domain forms a unique stoichiometric
(1:1), stable heterodimer complex with the hemopexin do-
main of MMP-9 proenzyme. This complex is significantly
more resistant to activation relative to the TIMP-1-free
MMP-9 proenzyme. Because TIMP-1 is highly expressed
in the naïve rat nerve [17, 18] and is further upregulated
concomitantly to MMP-9 in the acute phase of nerve
injury [17, 18], MMP-9 is found predominantly as a latent
inactive proenzyme [7, 8, 17, 18].
Whether MMP-9 is expressed and active in late-phase
painful peripheral nerve injury remains unknown. In light
of the emerging evidence of sexual dimorphism in neu-
roimmune pathogenesis of neuropathic pain progression
after peripheral nerve injury [2], we here aimed to deter-
mine the patterns of MMP-9 expression, activity, and ex-
cretion utilizing a widely used model of painful peripheral
neuropathy, rat sciatic nerve chronic constriction injury
(CCI) in female and male rats. Our results evidence exces-
sive, uninhibited proteolytic MMP-9 activity in late-phase
(day 28) post-CCI and suggest that the roles of MMP-9 in
peripheral neuropathy are universal in both sexes.
Results
In the peripheral nerve, MMP-9 is a pro-inflammatory
protease essential in the initial immune response to in-
jury [6–16, 19]. Recent work has shown that acute/in-
nate and late-phase/adaptive immune response to nerve
trauma differentially contributes to the development of
neuropathic pain in male and female rodents, respect-
ively [2]. In the present study, utilizing a well-established
model of sciatic nerve CCI mononeuropathy in male
and female rats, we tested whether MMP-9 contributes
to late-phase painful peripheral nerve trauma or whether
the changes in MMP-9 expression, proteolytic activity,
or excretion post-CCI are sexually dimorphic.
Time course of MMP-9 and TIMP-1 expression in sciatic
nerve post-CCI
There is a consensus that the MMP-9:TIMP-1 ratio largely
determines the net proteolytic activity of the MMP-9
Fig. 1 Late-phase MMP-9, but not TIMP-1, mRNA upregulation in the nerve post-CCI. Taqman qRT-PCR for MMP-9 (a) and TIMP-1 (b) in female rat
sciatic nerve at day 0 (naïve) and days 1, 3, 5, 7, 14, 28, and 60 post-CCI. The mean relative mRNA ± SEM of n = 4/group was normalized to
GAPDH, calibrated to the naïve nerve, and analyzed by one-way ANOVA and Tukey’s post hoc test (****p < 0.0001; ***p < 0.001; n.s., non-
significant, compared to the naïve nerve). c The fold difference in the MMP-9 (black) and TIMP-1 (gray) mRNA levels at day 1 and day 28 post-CCI
in (a, b). Expressed as a percentage relative to the respective value at day 1 (= 100%)
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enzyme. We used our established Taqman qRT-PCR
methods [7, 10, 12, 18] to quantify the relative MMP-9 and
TIMP-1 expression levels and MMP-9:TIMP-1 expression
ratio in the sciatic nerve between day 0 and 60 post-CCI in
female rats (Fig. 1). As females are prevalent sufferers of
chronic pain [20, 21], historically [7–13, 22, 23] and ini-
tially in the present study, we used female rats. In the naïve
sciatic nerve (day 0), MMP-9 mRNA level was exceedingly
low, whereas the TIMP-1 mRNA level was high (Fig. 1a).
After CCI injury, MMP-9 mRNA level at the nerve injury
site increased within 1 day and persisted for several weeks,
escalating again at day 28 post-CCI. Relative to the naïve
nerve, TIMP-1 mRNA peaked at day 1 post-CCI but then
declined over the time course (Fig. 1b). At day 28 post-
CCI, the levels of TIMP-1 and MMP-9 were reduced ~ 5-
fold and increased ~ 9-fold relative to day 1, respectively
(Fig. 1c). These findings suggested that in the injured nerve
microenvironment, the MMP-9:TIMP-1 ratio likely shifted
in favor of MMP-9 enzyme at day 28 post-CCI relative to
day 1; although due to the high basal level of the TIMP-1
expression in adult rat nerve [7, 17], the presence of
TIMP-1-free MMP-9 activity at day 28 post-CCI cannot be
assumed. We next aimed to confirm the presence of active
MMP-9 at day 28 post-CCI.
Late-phase proteolytic MMP-9 activity in female and male
CCI nerve
To confirm the presence of active MMP-9 at late-phase
nerve injury, we performed gelatin zymography of crude
nerve extracts at two critical time points in which the
MMP-9 mRNA level increased (days 1 and 28 post-CCI)
in female rat nerves (Fig. 2). Contralateral female rat
nerve at day 1 post-CCI served as control. In addition,
prior to analysis by gelatin zymography, we purified
MMP-9 from the nerve extracts using gelatin-Sepharose
beads that capture MMP-9 via its gelatin-binding site, a
repeat of three fibronectin type-II modules inserted in
the catalytic domain [24]. In both the crude and purified
samples, MMP-9 was not detected in the normal nerve
(day 0), whereas MMP-9 was dramatically upregulated
in the injured nerve at day 1 post-CCI (Fig. 2). The
gelatinolytic activity bands in the injured nerve samples
corresponded to the known species of MMP-9 that in-
cluded the 92-kDa proenzyme, the 84-kDa active mature
enzyme, the 120–125-kDa MMP-9●TIMP-1 complex, and
the multiple 200–260-kDa MMP-9 homo/heterodimers
[4, 7, 25] and was consistent with our prior observations
[7, 8]. A significant increase in the 84-kDa active, mature
MMP-9 enzyme was particularly evident in the nerve
samples at day 28 post-CCI in female rats. Both the
MMP-2 proenzyme and the active enzyme were detect-
able in normal and, at higher levels, injured CCI nerves,
consistent with prior observations [6–16].
Because the late-phase, adaptive immune response to
painful nerve injury differs in female and male rodents
[2], we comparatively assessed sensitivity to pain using
von Frey testing and then the late-phase MMP-9 activity
in nerves using gelatin zymography in female and male
rats at day 28 post-CCI. Both female and male rats dis-
played sustained pain hypersensitivity at week 4 post-CCI
(Fig. 3a), consistent with the findings of others [26–29].
Relative to the normal contralateral to injury (day 0)
nerves, MMP-9 at the nerve injury site (day 28) was
upregulated and activated similarly in female and male
samples (Fig. 3b). No significant difference was observed
in the intensity and the species of MMP-9 or MMP-2
bands between the female and male nerves (Fig. 3b).
There was also no apparent difference seen in the
distribution of MMP-9 immunoreactivity at day 28
post-CCI between the female and male nerves (Fig. 3c).
In both groups, MMP-9 reactivity was observed in
various cells, including crescent Schwann cells, as con-
firmed by dual-immunofluorescence for MMP-9 and
Schwann cell marker, S100 (Fig. 3c).
Together, these data confirm the earlier observation of
the injury-specific MMP-9 upregulation in Schwann cells
and other cells of peripheral nerve [6–16] and provide the
first evidence for a drastic increase in MMP-9 expression
and catalytic activity in the late-phase painful neuropathy,
which is comparable in female and male rodents.
Post-nerve injury MMP excretion via the urine in female
and male rats
Glycoproteins, including MMP-9, are normally excreted
via the urine [30, 31]. Protease levels are increased in
Fig. 2 Late-phase catalytic MMP-9 activity in the nerve post-CCI.
Gelatin zymography of the crude sciatic nerve extract (10 μg each;
CRUDE) and the purified MMP-9 samples (from 25 μg total extract
each; PURIFIED) isolated at day 0 (contralateral to injury, at day 1)
and days 1 and 28 post-CCI in female rats (representative of
n = 4/group). MMP-9 the latent MMP-9 control from HT1080 cells
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the urinary proteome of painful (diabetic) neuropathy
patients [32]. MMP-9 is a glycoprotein with multiple O-
glycosylation sites in the linker region between the cata-
lytic and hemopexin domains, and two N-glycosylation
sites in the inhibitory prodomain [33–35]. To investigate
if the observed increase in MMPs in the injured nerve
was followed by an elevated MMP excretion in the urine
and if the urinary MMP excretion was distinct in males
and females, we employed two independent methods to
assess protolytic MMP activity in the rat urine samples:
(1) the total MMP activity using the Mca-PLGL-Dpa-
AR-NH2 fluorescent peptide as a broad-specificity MMP
cleavage substrate (Fig. 4a) and (2) gelatin zymography
(Fig. 4b) analyses.
To estimate the total MMP activity in the urine sam-
ples before and after CCI, we first used the Mca-PLGL-
Dpa-AR-NH2 fluorescent peptide as a broad-specificity
MMP cleavage substrate (Fig. 4a). To limit interference
of the impurities in the crude samples with the fluoro-
genic substrate assay, we dialyzed the urine against the
MMP buffer, pH 7.5, prior to the assay. To determine
the specific MMP cleavage of the substrate, the dialyzed
samples were incubated with the Mca-PLGL-Dpa-AR-
NH2 substrate in the presence and absence of GM6001,
a broad-range hydroxamate inhibitor of MMPs. In fe-
male rats, there was a significant, roughly 5–6-fold
increase in the total MMP activity in the day 1 urine
samples post-CCI relative to day 0. The elevated urinary
MMP activity, still by 3-fold relative to prior nerve in-
jury, sustained at least until day 28 post-CCI. Since
GM6001 greatly repressed the cleavage activity in the
urine samples, we concluded that non-MMP proteases
did not significantly contribute to the substrate cleavage.
To support these findings, we examined the status of the
gelatinolytic MMPs in the rat urine samples using gelatin
zymography (Fig. 4b). The level of the urinary MMP activ-
ity in the sample at day 0 was below detection limit, except
for one gelatinolytic band. Relative to day 0, there was a sig-
nificant increase in the urinary MMPs at day 1 post-CCI
that persisted until day 28 post-CCI. To confirm the MMP
identity of the gelatinolytic bands, we used EDTA, a metal
chelator and a general inhibitor of zinc-MMPs. EDTA re-
pressed all of the MMP-related gelatinolytic bands in the
samples, except a single EDTA-resistant band in the day 0
samples, suggesting the presence of minor non-MMP gela-
tinolytic activity in the normal rat urine.
To compare the MMP excretion patterns in female
versus male rats post-CCI, we quantified the MMP-
specific activity levels in the urine before (day 0) and at
day 28 post-CCI in the same animal cohort (Fig. 4c).
The measurements demonstrated that, although males
exhibited an elevated constitutive urinary MMP activity
compared with females, the change in MMP activity at
day 28 post-CCI relative to the respective pre-injury
control increased similarly in males and females (~ 40–
50 RFU/μg total protein). Overall, an enhanced MMP ex-
cretion in the urine corroborates the MMP upregulation
in the injured nerve that is universal in both sexes.
Discussion
Despite the high regenerative capacity of the peripheral
nerve, nerve trauma often results in poor functional
Fig. 3 Late-phase MMP-9 in female and male nerves post-CCI. a von Frey testing in female and male rat CCI ipsilateral and contralateral to injury
in hind paws. The graph represents the mean withdrawal thresholds (gram force, g) ± SEM, displaying significant allodynia in both female and
male animals at day 28 post-CCI in the ipsilateral hind paw (*p≤ 0.05). b The status of catalytic MMP-9 activity in the sciatic nerve in female and
male rats. Gelatin zymography of the purified MMP-9 samples (from 25 μg total extract each; PURIFIED) isolated at day 28 post-CCI contralateral
(day 0) and ipsilateral (day 28 post-CCI) to injury (representative of n = 4/group). c Left panel: MMP-9 immunostaining (red) in the sciatic nerve in
female and male rats at 4 weeks post-CCI (representative of n = 3/group). Scale bar, 50 μm. Right panel: MMP-9 (red) and S100 (green) dual
immunostaining in female nerve demonstrates that Schwann cells (white arrows) and other cells (blue arrowheads) produce MMP-9 at day 28
post-CCI. Scale bar, 25 μm
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recovery and debilitating neuropathic pain [36–38].
Chronic neuroinflammation is a major contributing factor
in the development of neuropathic pain [39–41].
Chronic constriction injury (CCI) to rat sciatic nerve is
an animal model for the study of the mechanisms
underlying clinically relevant pain-like behaviors from
normally painless stimuli (allodynia) and exaggerated
pain from painful stimuli (hyperalgesia) sustained for
weeks after incitement of CCI [26–29]. In the models
of painful peripheral neuropathy, the MMP enzyme
family has multiple established and critical roles in im-
mune cell recruitment and demyelination and the de-
velopment of neuropathic pain [6–16, 19, 39, 42].
MMP-9 is a unique early-response proinflammatory
MMP family member induced in adult nerve exclusively
after injury, including CCI [6, 8, 10–12, 14, 23, 43–45],
as confirmed in the present study. Proinflammatory cy-
tokines, including TNF-α and IL-1β, stimulate MMP-9
expression in Schwann cells and endothelial cells of the
nerve [11, 12]. Infiltrating immune cells, such as neutro-
phils and macrophages, serve as additional sources of
MMP-9 in the damaged nerve. A number of the early-
phase MMP-9 activities in nerve injury have been estab-
lished, including immune cell infiltration, suppression of
Schwann cell mitosis, and promoting demyelination by
degradation of myelin protein [7–12, 44]. In addition to tis-
sue remodeling at the nerve injury site, MMP-9 is thought
to contribute to pro-nociceptive dorsal spinal cord plasti-
city after peripheral nerve injury [6, 46, 47]. In support of
the net proinflammatory early-phase gelatinolytic activity
in painful neuropathy, systemic acute MMP-9/2 inhibition
at day 1 post-CCI prevents the development of neuro-
pathic pain [8]. In addition, broad-spectrum MMP inhib-
ition [44] and MMP-9 targeting using siRNA [19] protect
from nerve injury-induced pain.
The present study offers the first evidence that MMP-
9 expression and activity are elevated in the nerve
during late-phase nerve injury. Because of a multi-fold
shift of the MMP-9:TIMP-1 ratio in favor of MMP-9,
the excess MMP-9 activity was unencumbered by its
endogenous inhibitor TIMP-1 specifically during the
late-phase. These data are in contrast to the findings of
the early-phase MMP-9 increase as inactive pro-enzyme
and add significantly to the previous studies implicating
the early-phase action of MMP-9 in pain [8, 19, 44]. In
addition to pain, the early-phase Schwann cell anti-
mitogenic MMP-9 action during the first days post-nerve
crush affects long-term nerve repair in part by regulating
Schwann cell numbers in the regenerating nerve [7, 9, 10].
Using MMP-9 knockout animals, we have established the
Fig. 4 MMP excretion in female and male rats post-CCI. a MMP activity in urine of female rats. The urine samples collected at day 0 (prior to injury)
and days 1 and 28 post-CCI (n = 4/group) were equilibrated in MMP buffer, pH 7.5, and then the protein concentrations were determined using the
Bradford assay and made even by sample dilution in MMP buffer, pH 7.5. Dialyzed urine (50 μl each) was co-incubated with the fluorescent Mca-PLGL-
Dpa-AR-NH2 MMP substrate. Where indicated, GM6001 (10 μM) was added to the samples to inhibit MMP activity. The numbers indicate the MMP-
specific cleavage activity. Data are means ± SD from multiple individual measurements performed at least in duplicate. b Gelatin zymography of female
rat urine (5 μl of each normalized sample) collected at day 0 and days 1 and 28 post-CCI (representative of n = 4/group). Gels were incubated in the
absence and the presence of 20 mM EDTA (− EDTA and + EDTA, respectively). c Specific urinary MMP activity in female and male rats. The urine
samples collected at day 0 and 28 post-CCI (n = 4–5/group) were equilibrated in MMP buffer, pH 7.5, and then the protein concentrations were
determined using the Bradford assay. Dialyzed urine samples (50 μl, each) were co-incubated with the fluorescent Mca-PLGL-Dpa-AR-NH2 MMP
substrate in the presence and the absence of GM6001 (10 μM). The specific MMP activity (RFU without GM6001–RFU with GM6001) was normalized to
the protein concentrations. Data are means ± SD from multiple individual measurements performed at least in duplicate. RFU relative fluorescence unit,
MMP-9 the latent MMP-9 control from HT1080 cells, NS non-MMP activity band
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essential role of MMP-9 in voltage-gated sodium (Nav)
channel clustering in the nodes of Ranvier, and MMP-9
deletion resulted in excessively large Nav channel clusters
at 1 month post-crush [7]. This finding suggests that by
regulating remyelination, MMP-9 may contribute to pain
resolution. Insofar, the direct pro-regenerative role of gela-
tinases in the sciatic nerve has been attributed to MMP-2,
and not MMP-9, via degradation of growth-inhibitory
proteoglycans [48, 49].
The peripheral nerve comprises a plethora of MMP-9
substrates. By regulation of the cleavage and the release
of soluble cytokine and trophic factor ligand and recep-
tors from their membrane isoforms, MMP-9 activity
regulates activation and inactivation of cytokine and
trophic pathway in the damaged nerve [10, 39, 43]. By
proteolytic fragmentation of myelin basic protein (MBP)
and myelin-associated glycoprotein (MAG) of nerves,
MMP-9 activity promotes demyelination and the release
of the pro-algesic MBP [8, 22, 50] and growth-inhibitory
MAG [51] fragments, respectively. MMP-9 controls Nav
channel clustering in the injured nerve by proteolysis of
laminin and dystroglycan, both required for Nav cluster-
ing [7, 52], or by direct proteolysis of the extracellular
loop region of Nav channels [53]. The evidence of the
active MMP-9 species in the nerve at the late-phase
painful neuropathy offers a possibility for MMP-9 role in
pain sustenance or resolution via control of nerve regen-
eration, demyelination, and ion channel functioning.
Our studies also indicate multiple roles of catalytic
MMP-9 (defined by inhibition using GM6001 inhibition)
in Schwann cell signaling; it produced a bi-phasic ERK1/
2 activation by proteolytic activation of insulin-like
growth factor 1, epidermal growth factor, and platelet-
derived growth factor signaling pathways [10]. In turn,
by inhibiting excess MMP-9 proteolysis, TIMP-1 is ex-
pected to promote nerve regeneration and remyelination
[7, 18] and to inhibit the development of neuropathic
pain [19, 54]. Our data suggest that insufficient TIMP-1
level to limit late-phase MMP proteolysis in the dam-
aged nerve provides rationale for the use of late-phase
TIMP-1-based therapy in painful neuropathy.
In addition to proteolysis of extracellular proteins
and protein domains [55, 56], MMP-9 regulates cell
behavior by direct receptor binding [25, 57–59]. The
unique representation of the multiple MMP-9 iso-
forms, including the proenzyme, mature enzyme,
homodimers, and heterodimers, in the injured nerve
suggests its complex and multiple roles. At day 1 post-
CCI, high levels of inactive MMP-9 proenzyme are
consistent with high TIMP-1 level. In excess of latent
MMP-9 over TIMP-1, MMP-9 proenzyme free from
TIMP-1 is activated by plasmin or MMP-3 [60]. In
addition, MMP-9 proenzyme may be involved in sig-
naling neurite growth or Schwann cell migration
through interaction of the non-catalytic hemopexin
domain with low-density lipoprotein receptor-related
protein-1 [61, 62] or through the cell surface complex
with CD44, mediating TIMP-1-induced survival sig-
naling [63]. Thus, the spatial and temporal relation of
the specific MMP-9 and TIMP-1 species and binding
partners will determine the functional outcomes of
their individual and joint activities in painful periph-
eral neuropathy.
MMP-9 is a glycoprotein with multiple O-glycosyla-
tion sites in the linker region between the catalytic and
hemopexin domains and, in addition, two well-defined
N-glycosylation sites—one in the prodomain and an-
other in the catalytic domain [33–35]. A majority of the
secretory and cell surface proteins that are shed into
the urine are glycosylated [30, 64]. The urinary MMPs
are elevated in multiple cancer and nephropathy types,
osteoarthritis, and heart failure [31, 65–68] and consti-
tutively in male compared to female rat urine. Similarly,
we recorded a significant increase in the total MMP
cleavage activity as well as the presence of the elevated
levels of the multiple MMP species in rat urine post-
nerve injury. While the non-invasive experimental
urine measurements readily distinguished animals with
painful neuropathy from normal animals, the presence
of non-neuropathic conditions with elevated urinary
MMPs [31, 65–68] cannot be excluded in the clinical
setting. Nevertheless, characterization of urinary extra-
cellular vesicles present considerable research interest
due to their possible use as a source of biomarkers and
have been shown to contain proteases in patients with
diabetic neuropathy [32].
Understanding the influence of biological variables,
including subject’s sex, on pathophysiology of painful
neuropathy is critical to the development of personal-
ized therapeutic and diagnostic approaches. Because
females are more common sufferers of chronic pain
[20, 21], our historical [7–13, 23] and initial experi-
ments in the present study employed female rat CCI.
Comparative studies of immune response to nerve in-
jury in female and male rodents indicated clearly that
immunotherapeutic targeting of mechanical allodynia is
sex-dependent [2]. Because MMP-9 expression, activity,
and excretion are universal in female and male rats
with painful neuropathy, in the search for selective
markers of nerve injury and neuropathic pain, MMP-9
presents a reliable, injury-specific surrogate biomarker
regardless of subject’s sex.
Conclusion
In conclusion, the present study offers the first evidence
for the excessive, uninhibited proteolytic MMP-9 activity
during late-phase painful peripheral neuropathy and
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suggests that the pattern of MMP-9 expression, activity,
and excretion after peripheral nerve injury is universal in
both sexes. Future studies identifying detrimental and
beneficial roles of MMP-9 in pain resolution and nerve
repair in late-phase nerve injury are warranted.
Methods
Reagents
All reagents were purchased from MilliporeSigma unless
indicated otherwise. The horseradish peroxidase (HRP)-
conjugated goat anti-rat IgM (#3020-05) was purchased
from Southern Biotech. The HRP-conjugated goat anti-rat
IgG (#112-035-175) and the [(7-methoxycoumarin-4-yl)a-
cetyl]-Pro-Leu-Gly-Leu-[N-3-(2,4-dinitrophenyl)-L-2,3-dia-
mino-propionyl]-Ala-Arg-NH2 (Mca-PLGL-Dpa-AR-NH2)
fluorescent MMP substrate were obtained from Jackson
ImmunoResearch and R&D Systems, respectively. A
3,3′,5,5′-tetramethylbenzidine substrate (TMB/E) and
protease-free BSA (a 30% solution) were from Surmodics
and US Biological, respectively. Gelatin-Sepharose 4B
beads and Micro Bio-Spin columns were from GE Health-
care and Bio-Rad, respectively. The Coomassie protein
assay reagent and Novex 10% zymogram (0.1% gelatin)
gels were purchased from Thermo Scientific.
Animal model and sample collection
Sixty adult female and 20 male Sprague-Dawley rats (200–
225 g) were obtained from Envigo Labs and housed in a
temperature-controlled room (22 °C) on a 12-h light/dark
cycle with free access to food and water. Following
anesthesia with 4% isoflurane in oxygen (Aerrane; Baxter),
the common sciatic nerve was exposed unilaterally at the
mid-thigh level. The nerve received three loosely constrict-
ive chromic gut ligatures to produce CCI [26]. At days 0–
60 post-CCI, urine sample aliquots (0.2–0.4 ml) were
collected, readily placed on ice for a few minutes, and then
cleared by centrifugation (2,000×g; 10 min; 4 °C). Cleared
urine aliquots were equilibrated in 50 mM HEPES, pH 7.5,
containing 10 mM CaCl2, 0.5 mM MgCl2, and 10 μM
ZnCl2 (MMP buffer, pH 7.5), using a desalting spin column
and immediately used in the MMP activity tests. Sciatic
nerve samples were collected and snap-frozen in liquid N2
and stored at − 80 °C for protease activity assays and in
RNA-later and stored at − 20 °C for the qRT-PCR analyses.
For immunohistochemistry, sciatic nerves were isolated
following transcardial perfusion in 4% paraformaldehyde in
0.2 M phosphate, post-fixed and embedded in paraffin.
Animals were sacrificed using Beuthanasia (150 mg/ml; i.p.,
Schering-Plough Animal Health). All animal procedures
were performed according to the PHS Policy on Humane
Care and Use of Laboratory Animals and the protocol
approved by the Institutional Animal Care and Use Com-
mittee at the VA San Diego Healthcare System.
von Frey testing
Rats were habituated to the testing environment prior to
baseline tests. Testing was performed daily for 3 con-
secutive days prior to and then at the indicated time
points after CCI. Rats were placed in individual Plexiglas
compartments with wire mesh bottom, and von Frey
filaments (0.41–15.2 g, Stoelting) were applied perpen-
dicularly to the mid hind paw and held for 4–6 s. A
positive response was noted if the paw was sharply with-
drawn. The 50% probability of withdrawal threshold was
determined by Dixon’s up-down method [69].
Taqman qRT-PCR
Taqman primers and a probe containing 5′-FAM re-
porter for rat TIMP-1 (GenBank, NM_053819) were
from Applied Biosystems (cat. # Rn01430873_g1).
Primers and probes for MMP-9 (GenBank, NM_031055)
and glyceraldehyde 3-phosphate dehydrogenase (GAPDH;
GenBank, X02231) were from Biosearch Technologies
[8, 12]. Total RNA was extracted using TRIzol and
purified on an RNeasy mini column (Qiagen). The
RNA purity was estimated by measuring the A260/280
and the A260/230 ratios. The samples were treated with
RNase-free DNAse I (Qiagen). cDNA was synthesized
using a first-strand cDNA kit (Roche). Gene expres-
sion levels were measured in a Mx3005P (Agilent)
using 50 ng cDNA and 2×Taqman Universal PCR
Master Mix (Applied Biosystems) with a one-step
program: 95 °C, 10 min; 95 °C, 30 s; 60 °C, 1 min for
50 cycles. Using the injured sciatic nerve cDNA sam-
ples, primers (Biosearch Technologies) and Taqman
probes for MMP-9 (Roche) and TIMP-1 (Applied Bio-
systems) were optimized to reach the amplification effi-
ciency of 100.1–100.3% [12]. GAPDH was used as a
normalizer; its expression changes were insignificant in the
injured relative to naïve nerves. Samples without cDNA (a
no template control) showed no contamination. Relative
mRNA levels were quantified using the comparative delta
Ct method [70]. The fold change between CCI and naïve
samples was determined using the Mx3005P software.
Protease activity assay
The cleavage assay was performed in a 0.2-ml total volume
in wells of a 96-well plate (Thermo Scientific) using the
fluorescent Mca-PLGL-Dpa-AR-NH2 peptide substrate
(1 μM) and the 50-μl urine aliquots equilibrated in the
MMP buffer, pH 7.5. Where indicated, GM6001 (10 μM)
was co-incubated for 30 min at ambient temperature with
the urine samples to inactivate MMPs. Initial reaction vel-
ocity was monitored continuously at λex = 320 nm and λem
= 400 nm using a fluorescence spectrophotometer. Data are
means ± SD from several independent experiments per-
formed at least in duplicate. Protein concentrations in the
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dialyzed urine samples were determined using the Coomas-
sie protein assay.
MMP-9 purification using gelatin-Sepharose beads
The proteins were extracted for 1 h at 4 °C from the
sciatic nerve samples using 50 mM Tris-HCl buffer,
pH 7.4, containing 150 mM NaCl, 1% Triton X-100,
0.1% SDS, 10 mM EDTA, the protease cocktail inhibitor,
and 1 mM phenylmethylsulfonyl fluoride. The protein
concentration of the extracts was determined using the
Coomassie protein assay and adjusted to reach 1 mg/ml.
The extract aliquots (100 μg total proteins, each) were
10-fold diluted using the above buffer lacking Triton X-
100 and SDS and allowed to bind to gelatin-Sepharose
4B beads for 16–18 h at 4 °C. Following extensive wash-
ing, the bound material was eluted using non-reducing
2×SDS sample buffer (50 μl).
Gelatin zymography
The dialyzed rat urine samples equilibrated in MMP
buffer, pH 7.5; the crude nerve extracts; and the MMP-9
samples isolated from sciatic nerve were analyzed by gel-
atin zymography in a 10% acrylamide-0.1% gelatin gel.
Gels were next processed as described previously to
visualize the clear gelatinolytic activity bands [7, 8].
Where indicated, gels were incubated in 20 mM EDTA
to inactivate MMP activity.
Immunohistochemistry
Transverse (10-μm-thick) sciatic nerve sections collected
at 4 weeks post-CCI after transcardial perfusion in 4%
paraformaldehyde in 0.2 M phosphate, post-fixed and em-
bedded in paraffin, were deparaffinized in xylenes and
rehydrated in graded ethanol. Following endogenous
aldehyde group block (0.5% sodium borohydride in 1%
sodium dibasic buffer for 5 min) and non-specific binding
block (5% goat serum in PBS for 30 min at room
temperature), nerve sections were incubated with a rabbit
polyclonal antibody to MMP-9 (1:500; Torrey Pines Bio-
labs, 16–18 h at 4 °C) alone or with rabbit polyclonal anti-
body to MMP-9 (1:50; SantaCruz, 16–18 h at 4 °C)
sequentially with mouse monoclonal antibody to S100
(1:2000, Sigma, 16–18 h at 4 °C), followed by the respect-
ive species-specific Alexa 594 (red) or Alexa 488 (green)-
conjugated secondary antibody (ThermoFisher Scientific,
1 h, room temperature, each). PBS was used for rinsing.
Slowfade Gold antifade reagent containing DAPI (4′,6-
diamidino-2-phenylindole, ThermoFisher Scientific, blue)
was used for mounting. Staining specificity was confirmed
by a primary antibody omission. The images were ac-
quired using All-In-One Fluorescence Microscope BZ-
X700 (Keyence, Itasca, IL).
Statistical analyses
Statistical analyses were performed using Graph Prism 6
(Synergy Software) or SPSS 16.0 (SPSS) software by a two-
tailed, unpaired Student’s t test or one-way analyses of
variance (ANOVA) with multiple comparisons followed
by Tukey’s post hoc test. p ≤ 0.05 values were considered
significant.
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